Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Medikaloka Hermina TbkISX:HEAL -1.85%70 Return-on-Tangible-Equity is 7.11% as of Mar. 2026, which is 40% below its 10-year median of 11.91. GuruFocus rates ISX:HEAL with a GF Score™ of 70/100 and a GF Value™ of Rp1,587.70 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 576 Healthcare Providers & Services companies, PT Medikaloka Hermina Tbk ranks worse than 58.16% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PT Medikaloka Hermina Tbk's annualized net income for the quarter that ended in Mar. 2026 was Rp405,048 Mil. PT Medikaloka Hermina Tbk's average shareholder tangible equity for the quarter that ended in Mar. 2026 was Rp5,696,830 Mil. Therefore, PT Medikaloka Hermina Tbk's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 7.11%.
The historical rank and industry rank for PT Medikaloka Hermina Tbk's Return-on-Tangible-Equity or its related term are showing as below:
ISX:HEAL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.91 Med: 11.91 Max: 33.68
Current: 7.51
During the past 11 years, PT Medikaloka Hermina Tbk's highest Return-on-Tangible-Equity was 33.68%. The lowest was 5.91%. And the median was 11.91%.
ISX:HEAL's Return-on-Tangible-Equity is ranked worse than 58.16% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.25
vs ISX:HEAL: 7.51
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
PT Medikaloka Hermina Tbk Return-on-Tangible-Equity Related Terms
PT Medikaloka Hermina Tbk Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for PT Medikaloka Hermina Tbk's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:HEAL vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, PT Medikaloka Hermina Tbk's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Medikaloka Hermina Tbk Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Medikaloka Hermina Tbk's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where PT Medikaloka Hermina Tbk's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.11% mean?
PT Medikaloka Hermina Tbk (ISX:HEAL) has a Return-on-Tangible-Equity of 7.11% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PT Medikaloka Hermina Tbk and its competitors. This is 40% below median its historical median of 11.91. Over the past decade, PT Medikaloka Hermina Tbk's Return-on-Tangible-Equity has ranged from 5.91 to 33.68. According to the industry distribution chart, PT Medikaloka Hermina Tbk ranks #335 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 58.2%.
Is PT Medikaloka Hermina Tbk's Return-on-Tangible-Equity too high?
PT Medikaloka Hermina Tbk's current Return-on-Tangible-Equity of 7.11% is 40% below median its 10-year median of 11.91. Over the past 10 years, this metric has ranged from a low of 5.91 to a high of 33.68. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.25. PT Medikaloka Hermina Tbk's value of 7.11% is 30.6% below this industry median. Based on the distribution chart, PT Medikaloka Hermina Tbk ranks #335 out of 576 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PT Medikaloka Hermina Tbk has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Medikaloka Hermina Tbk's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Medikaloka Hermina Tbk ranks #335 out of 576 companies for Return-on-Tangible-Equity. This places PT Medikaloka Hermina Tbk in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.25. PT Medikaloka Hermina Tbk's value of 7.11% is 30.6% below this benchmark. Historically, PT Medikaloka Hermina Tbk's own Return-on-Tangible-Equity has ranged from 5.91 to 33.68 over the past decade. While the company's 10-year median is 11.91 vs. the industry median of 10.25, PT Medikaloka Hermina Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.25, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Medikaloka Hermina Tbk's current Return-on-Tangible-Equity of 7.11% is 30.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PT Medikaloka Hermina Tbk and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Medikaloka Hermina Tbk's current Return-on-Tangible-Equity is 7.11%, which is 40% below median its own 10-year median of 11.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Medikaloka Hermina Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk (ISX:HEAL) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp1,587.70, compared to a current price of Rp795.00 — trading 49.9% below its estimated fair value. The current Return-on-Tangible-Equity is 7.11%, which is 40% below median its 10-year median of 11.91 and 30.6% below the Healthcare Providers & Services industry median of 10.25. PT Medikaloka Hermina Tbk's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For PT Medikaloka Hermina Tbk (ISX:HEAL), the current Return-on-Tangible-Equity is 7.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Medikaloka Hermina Tbk (ISX:HEAL) Overvalued in 2026?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk stock appears to be undervalued.
The current stock price of Rp795.00 is trading 49.9% below its estimated GF Value™ of Rp1,587.70.
GuruFocus considers PT Medikaloka Hermina Tbk to be Significantly Undervalued.
Key valuation signals for ISX:HEAL:
Return-on-Tangible-Equity: 7.11% (40% below median its 10-year median of 11.91)
GF Value™: Rp1,587.70 vs. price of Rp795.00 (49.9% below fair value)
Industry Position: 30.6% below the Healthcare Providers & Services median (#335 of 576)
No single metric tells the full story. See the ISX:HEAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Medikaloka Hermina Tbk is a private hospital group. It provides a range of medical services, including maternal and child health services, complex operating procedures, laboratory services, radiology facilities, and fertility treatments as well as general health services, pharmacies, diagnostic and emergency services. The company's geographical segment includes Kalimantan dan Sulawesi, Jawa, and Sumatera. It derives maximum revenue from the Jawa segment.
70GF Score
Get the complete analysis for ISX:HEAL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:HEAL has been successfully added to your 
